中国组织工程研究

中国组织工程研究 ›› 2012, Vol. 16 ›› Issue (39): 7395-7399.doi: 10.3969/j.issn.2095-4344.2012.39.035

• 骨与关节临床实践 clinical practice of the bone and joint • 上一篇    下一篇

阿仑膦酸钠和阿法骨化醇联合治疗严重骨质流失和骨质疏松性骨折

刘 锋1，张 君2，王文修1，张明强1，张志峰1，侯海涛1   

  1. 1河南省长垣县人民医院骨科，河南省长垣市 453400
    2新乡医学院第一附属医院骨科，河南省卫辉市 453100
  • 收稿日期:2012-05-02 修回日期:2012-07-11 出版日期:2012-09-23 发布日期:2012-09-23
  • 通讯作者: 刘锋★，男，1966年生，河南省郑州市人，汉族，2004年华北煤炭医学院毕业，硕士，主治医师，主要从事脊柱与关节外科、创伤骨科临床工作。 liufeng1237891@163.com
  • 作者简介:刘锋★，男，1966年生，河南省郑州市人，汉族，2004年华北煤炭医学院毕业，硕士，主治医师，主要从事脊柱与关节外科、创伤骨科临床工作。 liufeng1237891@163.com

Alendronate plus alfacalcidol for the treatment of severe bone loss and osteoporotic fractures

Liu Feng1, Zhang Jun2, Wang Wen-xiu1, Zhang Ming-qiang1, Zhang Zhi-feng1, Hou Hai-tao1   

  1. 1Department of Orthopedics, the People's Hospital of Changyuan, Changyuan 453400, Henan Province, China
    2Department of Orthopedics, the First Affiliated Hospital of Xinxiang Medical College, Weihui 453100, Henan Province, China
  • Received:2012-05-02 Revised:2012-07-11 Online:2012-09-23 Published:2012-09-23
  • Contact: Liu Feng, Master, Attending physician, Department of Orthopedics, the People's Hospital of Changyuan, Changyuan 453400, Henan Province, China Liufeng1237891@163.com
  • About author:Liu Feng★, Master, Attending physician, Department of Orthopedics, the People's Hospital of Changyuan, Changyuan 453400, Henan Province, China Liufeng1237891@163.com

PDF

942

摘要：

背景：阿仑膦酸钠和阿法骨化醇均可抑制骨质疏松性骨折患者骨转换，增加骨矿物密度。
目的：观察阿仑膦酸钠和阿法骨化醇联合治疗患有严重骨质流失和骨质疏松性骨折患者的效果。
方法：纳入严重骨质流失和骨质疏松性骨折患者，进行阿仑膦酸钠和阿法骨化醇联合治疗2年。
结果与结论：相比治疗前，阿仑膦酸钠和阿法骨化醇联合治疗后患者腰椎骨密度增加(P < 0.05)，随后尿Ⅰ型胶原N末端肽水平和血清碱性磷酸酶活性减少(P < 0.05)。证实，阿仑膦酸钠和阿法骨化醇联合治疗患有严重的骨质流失和骨质疏松性骨折患者疗效好。

关键词: 阿仑膦酸钠, 阿法骨化醇, 联合, 骨质流失, 骨质疏松性骨折, 组织工程

Abstract:

BACKGROUND: Alendronate and alfacalcidol can inhibit the bone transformation and increase bone mineral density of the patients with osteoporotic fractures.
OBJECTIVE: To investigate the effect of alendronate plus alfacalcidol for the treatment of severe bone loss and osteoporotic fractures.
METHODS: Patients with severe bone loss and osteoporotic fractures were selected, and then the patients were treated with alendronate plus alfacalcidol for 2 years.
RESULTS AND CONCLUSION: Compared with before treatment, the lumbar spine bone density of the patients was increased after treated with alendronate plus alfacalcidol (P < 0.05) followed by urine of type Ⅰ collagen N-terminal peptide levels and serum alkaline phosphatase activity decreased (P < 0.05). It confirmed that the alendronate plus alfacalcidol has good effect for the treatment of severe bone loss and osteoporotic fracture patients.

中图分类号: